ESR1 and cancer: A registry study65 on 250,195 women with early-stage breast cancer showed a lower hazard ratio (HR) for second primary cancer among estrogen receptor-positive (ER+) patients after preoperative radiotherapy compared with postoperative radiotherapy (BCS: HR 0.64, p < 0.0001).